ATLANTIC: another reason to investigate the disconnect between stent thrombosis and mortality?

Daniel Aradi; Dirk Sibbing

doi:10.1160/TH15-02-0159

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2015; 114(01): 9-10
DOI: 10.1160/TH15-02-0159

Current Controversies

Schattauer GmbH

ATLANTIC: another reason to investigate the disconnect between stent thrombosis and mortality?

Daniel Aradi

¹Department of Cardiology, Heart Center Balatonfüred, Hungary

²Semmelweis University, Heart and Vascular Center, Budapest, Hungary

,

Dirk Sibbing

³Medizinische Klinik und Poliklinik I, Klinikum der Universität München, Ludwig-Maximilians-Universität München, Munich, Germany

⁴DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany

› Author Affiliations

Abstract

Full Text

References

References
1 Windecker S. et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014; 35: 2541-2619.
2 Mehta S. et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358: 527-533.
3 Steinhubl SR. et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. J Am Med Assoc 2002; 288: 2411-2420.
4 Collet JP. et al. Pretreatment with P2Y12 inhibitors in non-ST-Segment-elevation acute coronary syndrome: an outdated and harmful strategy. Circulation 2014; 130: 1904-1914.
5 Dörler J. et al. Clopidogrel pre-treatment is associated with reduced in-hospital mortality in primary percutaneous coronary intervention for acute ST-elevation myocardial infarction. Eur Heart J 2011; 32: 2954-2961.
6 Aradi D. et al. Prognostic significance of high onclopidogrel platelet reactivity after percutaneous coronary intervention: systematic review and meta-analysis. Am Heart J 2010; 160: 543-551.
7 Cattaneo M. High on-treatment platelet reactivity--definition and measurement. Thromb Hae-most 2013; 109: 792-798.
8 Trenk D. et al. High on-treatment platelet reactivity and P2Y12 antagonists in clinical trials. Thromb Haemost 2013; 109: 834-845.
9 Hohlfeld T. et al. High on treatment platelet reactivity against aspirin by non-steroidal anti-inflammatory drugs--pharmacological mechanisms and clinical relevance. Thromb Haemost 2013; 109: 825-833.
10 Wallentin L. et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-1057.
11 Wiviott SD. et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-2015.
12 Montalescot G. et al. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. N Engl J Med 2013; 369: 999-1010.
13 Montalescot G. et al. Prehospital ticagrelor in ST-segment elevation myocardial infarction. N Engl J Med 2014; 371: 1016-1027.
14 Serebruany VL. et al. Significant excess of early deaths after prehospital ticagrelor: The ATLANTIC trial challenge. Thromb Haemost 2015; 113: 7-8.
15 Serebruany VL, Fortmann SD. Viewpoint: “under-utilisation of novel antiplatelet agents--myths, generics, and economics”. Thromb Haemost 2014; 112: 4-9.
16 Serebruany VL, DiNicolantonio JJ. Viewpoint: mismatch between the European and American guidelines on oral antiplatelet P2Y12 inhibitors after acute coronary syndromes. Thromb Haemost 2013; 110: 5-10.
17 Mauri L. et al. Twelve or 30 months of dual anti-platelet therapy after drug-eluting stents. N Engl J Med 2014; 371: 2155-2166.